Sort
51,593 grants matching “hepatitis”
Optimization of alpha-hydroxytropolones as novel inhibitors of the HBV RNaseH
$440,118John E Tavis · Saint Louis University · R01 · FY2019 · AI
Optimization of alpha-hydroxytropolones as novel inhibitors of the HBV RNaseH
$440,118John E Tavis · Saint Louis University · R01 · FY2018 · AI
Optimization of alpha-hydroxytropolones as novel inhibitors of the HBV RNaseH
$440,118John E Tavis · Saint Louis University · R01 · FY2017 · AI
Optimization of alpha-hydroxytropolones as novel inhibitors of the HBV RNaseH
$440,118John E Tavis · Saint Louis University · R01 · FY2020 · AI
Inhaled inhibitors of TGFB activation by integrins
$440,097Dean Sheppard · University Of California, San Francisco · P01 · FY2012 · HL
Lay Health Worker Model to Reduce Liver Cancer Disparities in Asian Americans
$440,081Hee-Soon Juon · Thomas Jefferson University · R01 · FY2014 · CA
Dissemination and Policy Core
$440,046Zachary Franklin Meisel · Weill Medical Coll Of Cornell Univ · P30 · FY2025 · DA
Nutrition, Infection and Hepatic Carbohydrate Metabolism
$440,032Owen P McGuinness · Vanderbilt University · R01 · FY2008 · DK
Mechanisms of hepatitis C virus persistence
$440,000Arash Grakoui · Emory University · R01 · FY2016 · AI
Creation of a transgenic pig model permissive to HBV infection
$440,000Robert Layne Kruse · University Of Texas Med Br Galveston · R21 · FY2025 · AI
A Phase 2 Trial of Leflunomide for the Treatment of COVIDâ19 in Patients with Solid Tumors and Hematologic Malignancies
$440,000Steven Terry Rosen · Beckman Research Institute/City Of Hope · P30 · FY2020 · CA
Polarizing T Cell Responses in vivo With Dendritic Cells
$440,000Bali Pulendran · Emory University · R37 · FY2010 · DK
Mechanisms of Lipid Droplet Protein Targeting
$440,000Tobias C Walther · Sloan-Kettering Inst Can Research · R35 · FY2025 · GM
Mechanisms of hepatitis C virus persistence
$440,000Arash Grakoui · Emory University · R01 · FY2014 · AI
Mechanisms of hepatitis C virus persistence
$440,000Arash Grakoui · Emory University · R01 · FY2015 · AI
Endonuclease-mediated disruption of latent HSV as curative therapy
$439,988Keith R Jerome · Fred Hutchinson Cancer Research Center · R01 · FY2020 · AI
Liver Tissue and Cell Distribution System (LTCDS)
$439,933Bartosz Grzywacz · University Of Minnesota · N01 · FY2019 · HD
THE ATHEROPROTECTIVE EFFECTS OF SR-BI
$439,932Massachusetts Institute Of Technology · R01 · FY2001 · HL
Regulation of Hepatic Lipid and Glucose Metabolism by PC-TP/StarD2
$439,906David E Cohen · Brigham And Women'S Hospital · R37 · FY2012 · DK
Roche 454 Genome Sequencer FLX
$439,900Richard B. Markham · Johns Hopkins University · S10 · FY2010 · RR
Early Detection of Liver Cancer
$439,850Drexel University · U01 · FY2004 · CA
AAV vectors for prevention and therapy of HCV infection
$439,834Christopher M. Walker · Research Inst Nationwide Children'S Hosp · R01 · FY2007 · AI
Rethinking the zinc-copper relationship in Wilson Disease
$439,784Jason L Burkhead · University Of Alaska Anchorage · R15 · FY2017 · DK
Human cytomegalovirus entry into epithelial and endothelial cells
$439,738David C. Johnson · Oregon Health & Science University · R01 · FY2010 · AI
Hepatitis B ESL Education for Chinese
$439,700Fred Hutchinson Cancer Research Center · R01 · FY2005 · CA